Daniel I Brierley
Overview
Explore the profile of Daniel I Brierley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
902
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jones L, Brierley D
Endocrinology
. 2025 Jan;
166(2).
PMID: 39813121
Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales with body weight, affecting more than 1 billion people worldwide. Excess body fat is...
2.
Montaner M, Denom J, Simon V, Jiang W, Holt M, Brierley D, et al.
Nat Commun
. 2024 Aug;
15(1):6941.
PMID: 39138162
Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion and holds significant pharmacological potential. Nevertheless, the regulation of energy homeostasis by centrally-produced GLP-1 remains partially understood. Preproglucagon cells, known to release GLP-1,...
3.
Wagner S, Brierley D, Leeson-Payne A, Jiang W, Chianese R, Lam B, et al.
Mol Metab
. 2023 Jan;
68:101665.
PMID: 36592795
Objective: Overweight and obesity are endemic in developed countries, with a substantial negative impact on human health. Medications developed to treat obesity include agonists for the G-protein coupled receptors glucagon-like...
4.
Trapp S, Brierley D
Br J Pharmacol
. 2021 Jul;
179(4):557-570.
PMID: 34323288
This review considers the similarities and differences between the physiological systems regulated by gut-derived and neuronally produced glucagon-like peptide 1 (GLP-1). It addresses the questions of whether peripheral and central...
5.
Brierley D, de Lartigue G
Br J Pharmacol
. 2021 Jun;
179(4):584-599.
PMID: 34185884
Here, we provide a focused review of the evidence for the roles of the vagus nerve in mediating the regulatory effects of peripherally and centrally produced GLP-1 on eating behaviour...
6.
Brierley D, Holt M, Singh A, de Araujo A, McDougle M, Vergara M, et al.
Nat Metab
. 2021 Feb;
3(2):258-273.
PMID: 33589843
The anorexigenic peptide glucagon-like peptide-1 (GLP-1) is secreted from gut enteroendocrine cells and brain preproglucagon (PPG) neurons, which, respectively, define the peripheral and central GLP-1 systems. PPG neurons in the...
7.
Ast J, Arvaniti A, Fine N, Nasteska D, Ashford F, Stamataki Z, et al.
Nat Commun
. 2020 Oct;
11(1):5160.
PMID: 33037231
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
8.
Holt M, Cook D, Brierley D, Richards J, Reimann F, Gourine A, et al.
Mol Metab
. 2020 May;
39:101024.
PMID: 32446875
Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used as anti-diabetic drugs and are approved for obesity treatment. However, GLP-1RAs also affect heart rate (HR) and arterial blood pressure (ABP) in...
9.
Ast J, Arvaniti A, Fine N, Nasteska D, Ashford F, Stamataki Z, et al.
Nat Commun
. 2020 Jan;
11(1):467.
PMID: 31980626
The glucagon-like peptide-1 receptor (GLP1R) is a class B G protein-coupled receptor (GPCR) involved in metabolism. Presently, its visualization is limited to genetic manipulation, antibody detection or the use of...
10.
Brierley D, Harman J, Giallourou N, Leishman E, Roashan A, Mellows B, et al.
J Cachexia Sarcopenia Muscle
. 2019 Apr;
10(4):844-859.
PMID: 31035309
Background: Muscle wasting, anorexia, and metabolic dysregulation are common side-effects of cytotoxic chemotherapy, having a dose-limiting effect on treatment efficacy, and compromising quality of life and mortality. Extracts of Cannabis...